Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254

Proteomics. 2006 Jun;6(11):3400-13. doi: 10.1002/pmic.200500821.


In the absence of a suitable carbohydrate-based vaccine, outer membrane vesicle (OMV) vaccines have been used to disrupt outbreaks of serogroup B meningococcal disease for more than 20 years. Proteomic technology provides physical methods with the potential to assess the composition and consistency of these complex vaccines. 2-DE, combined with MS, were used to generate a proteome map of an OMV vaccine, developed to disrupt a long-running outbreak of group B disease in New Zealand. Seventy four spots from the protein map were identified including the outer membrane protein (OMP) antigens: PorA, PorB, RmpM and OpcA. Protein identification indicates that, in addition to OMPs, OMV vaccines contain periplasmic, membrane-associated and cytoplasmic proteins. 2-D-DIGE technology highlighted differences between preclinical development batches of vaccines from two different manufacturers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Bacterial / chemistry*
  • Antigens, Bacterial / immunology
  • Bacterial Outer Membrane Proteins / chemistry*
  • Bacterial Outer Membrane Proteins / immunology
  • Electrophoresis, Gel, Two-Dimensional
  • Humans
  • Mass Spectrometry
  • Meningococcal Vaccines / chemistry
  • Meningococcal Vaccines / immunology*
  • Neisseria meningitidis, Serogroup B / immunology*
  • Proteomics


  • Antigens, Bacterial
  • Bacterial Outer Membrane Proteins
  • Meningococcal Vaccines